FDA approves Actemra to treat rare form of juvenile arthritis

Posted by Food and Drug Administration--Press Releases on Friday Apr 15, 2011 Under News

The U.S. Food and Drug Administration today approved Actemra (tocilizumab), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 years and older.

Be Sociable, Share!

Comments are closed.